ImmunAbs
Latest round
- Series C
Last raised
- Jul 2026
Total raised
- $79M
Investors
- 12
About ImmunAbs
Founded in 2017, and based in Seoul, South Korea, ImmunAbs Inc. is a drug development specializing company that provides various antibody screening and engineering technologies such as phage display, single B cell cloning, and bispecific antibody development. In July 2026, ImmunAbs Inc. ImmunAbs Inc. offers antibody screening and engineering technologies such as phage display, single B cell cloning, and bispecific antibody development. It offers treatment for autoimmune diseases.
Who invested in ImmunAbs
12 investors across 3 rounds
See all investors in ImmunAbs
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ImmunAbs
Who invested in ImmunAbs?
ImmunAbs has 12 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ImmunAbs raised?
ImmunAbs has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did ImmunAbs last raise money?
ImmunAbs's most recent round on record is a Series C, in Jul 2026.
What does ImmunAbs do?
Founded in 2017, and based in Seoul, South Korea, ImmunAbs Inc.
Where is ImmunAbs headquartered?
ImmunAbs is headquartered in Seoul, South Korea.
Which VCs invest in companies like ImmunAbs?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at ImmunAbs's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like ImmunAbs? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.